Leukemia, Myeloid, Acute: all 3,035 studies

Page 11 of 31. Open to participants first (746), then studies with results posted, then the rest; newest registration first within each.

• Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell TransplantationCompletedNCT02458235Phase 2Results posted
• Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)CompletedNCT02441803Phase 2Results posted
• Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger PatientsTerminatedNCT02433483Phase 2Results posted
• A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) MutationCompletedNCT02421939Phase 3Results posted
• Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02416908Phase 1/2Results posted
• Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia PatientsCompletedNCT02400281Phase 1/2Results posted
• Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia PatientsCompletedNCT02400255Phase 2Results posted
• Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid LeukemiaTerminatedNCT02399917Phase 2Results posted
• Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT02397720Phase 2Results posted
• MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML PatientsCompletedNCT02395822Phase 2Results posted
• FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid LeukemiaActive, not recruitingNCT02392429Phase 2Results posted
• A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML PatientsCompletedNCT02367456Phase 1Results posted
• Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02353143Phase 1Results posted
• Study of Ibrutinib in Subjects With Acute Myeloid LeukemiaTerminatedNCT02351037Phase 2Results posted
• SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission InductionCompletedNCT02348489Phase 3Results posted
• Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)TerminatedNCT02343939Phase 1/2Results posted
• Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02337478Phase 2Results posted
• Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid LeukemiaCompletedNCT02328755Phase 1/2Results posted
• Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)TerminatedNCT02323113Phase 1/2Results posted
• Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)TerminatedNCT02319369Phase 1Results posted
• A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.CompletedNCT02310321Phase 1/2Results posted
• An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid LeukemiaTerminatedNCT02305563Phase 1/2Results posted
• Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in RemissionTerminatedNCT02302846Phase 2Results posted
• Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic SyndromesCompletedNCT02296242Phase 1/2Results posted
• Phase 1 Study of SGI-110 in Patients With Acute Myeloid LeukemiaCompletedNCT02293993Phase 1Results posted
• A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous LeukemiaCompletedNCT02287233Phase 1/2Results posted
• CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid LeukemiaCompletedNCT02286726Phase 2Results posted
• A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 MutationsCompletedNCT02283177Phase 2Results posted
• Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN TrialActive, not recruitingNCT02275533Phase 2Results posted
• SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete RemissionTerminatedNCT02270463Phase 1/2Results posted
• Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior TransplantationTerminatedNCT02259348Phase 2Results posted
• Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid LeukemiaCompletedNCT02257138Phase 1/2Results posted
• A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)CompletedNCT02249091Phase 2Results posted
• An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS PatientsCompletedNCT02238925Phase 2Results posted
• Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHDCompletedNCT02220985Phase 2Results posted
• Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD MutationCompletedNCT02196857Phase 2Results posted
• A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML)TerminatedNCT02177812Phase 1Results posted
• A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative MalignanciesCompletedNCT02158858Phase 1/2Results posted
• Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid LeukemiaCompletedNCT02144675Phase 2Results posted
• Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in RemissionCompletedNCT02126553Phase 2Results posted
• Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative NeoplasmCompletedNCT02121418Not applicableResults posted
• Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid LeukemiaCompletedNCT02113982Phase 1/2Results posted
• Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML PatientsCompletedNCT02109744Phase 1/2Results posted
• AML Therapy With Irradiated Allogeneic CellsTerminatedNCT02105116Not applicableResults posted
• Pilot Study of Feasibility of Outpatient Daily High Dose Cytarabine as Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML)CompletedNCT02101983Not applicableResults posted
• Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaCompletedNCT02096055Phase 2Results posted
• Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)TerminatedNCT02096042Phase 1/2Results posted
• MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard TherapyTerminatedNCT02089230Phase 1/2Results posted
• Selinexor (KPT-330) in Older Patients With Relapsed AMLCompletedNCT02088541Phase 2Results posted
• Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT02085408Phase 3Results posted
• Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing ChemotherapyCompletedNCT02071901Phase 2Results posted
• Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell TransplantTerminatedNCT02065869Phase 1/2Results posted
• A Pilot Study of Dociparstat Sodium (ODSH) in Acute Myeloid LeukemiaCompletedNCT02056782Phase 1Results posted
• Adoptive Transfer of Haplo-identical DLI for AML and MDSCompletedNCT02046122Phase 1/2Results posted
• Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromesCompletedNCT02044796Phase 1/2Results posted
• (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD PositiveCompletedNCT02039726Phase 3Results posted
• A Study Of PF-04449913 In Japanese Patients With Select Hematologic MalignanciesCompletedNCT02038777Phase 1Results posted
• Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell TransplantTerminatedNCT02038153Phase 1/2Results posted
• Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02030405Phase 2Results posted
• Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid LeukemiaTerminatedNCT02029417Phase 2Results posted
• CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT02019069Phase 2Results posted
• Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02014558Phase 1/2Results posted
• Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and MyelodysplasiaCompletedNCT02007863Not applicableResults posted
• Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML)TerminatedNCT02003573Phase 1Results posted
• Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant RelapseCompletedNCT01995578Phase 2Results posted
• A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)CompletedNCT01994837Phase 2Results posted
• Use of Saline-Washed Platelet and Red Cell Transfusions in Adult Acute LeukemiaCompletedNCT01976442Results posted
• A Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid LeukemiaCompletedNCT01961882Phase 2Results posted
• Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid LeukemiaTerminatedNCT01960387Phase 2Results posted
• Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD PreventionCompletedNCT01951885Phase 3Results posted
• A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic MalignanciesCompletedNCT01943851Phase 2Results posted
• Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML PatientsCompletedNCT01929408Results posted
• Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT01912274Phase 2Results posted
• Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid LeukemiaTerminatedNCT01907815Phase 2Results posted
• Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous LeukemiaCompletedNCT01904136Phase 1/2Results posted
• Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)TerminatedNCT01898793Phase 1/2Results posted
• Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaStatus unknownNCT01894477Phase 2Results posted
• Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic SyndromeCompletedNCT01893320Phase 1/2Results posted
• Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT01892371Phase 1/2Results posted
• IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCTCompletedNCT01885897Phase 1/2Results posted
• Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AMLCompletedNCT01883362Phase 2Results posted
• A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic SyndromeTerminatedNCT01880437Phase 2Results posted
• Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid LeukemiaTerminatedNCT01876953Phase 1/2Results posted
• Omacetaxine for Consolidation and MaintenanceTerminatedNCT01873495Phase 2Results posted
• Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity AssayCompletedNCT01872819Not applicableResults posted
• Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid LeukemiaCompletedNCT01870596Phase 2Results posted
• Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute LeukemiaCompletedNCT01869777Not applicableResults posted
• Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive ChemotherapyCompletedNCT01869114Phase 2Results posted
• Preventing Stem Cell Transplant Complications With a Blood Separator MachineCompletedNCT01866839Phase 1/2Results posted
• A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AMLCompletedNCT01861002Phase 1Results posted
• Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in ChildrenCompletedNCT01858740Phase 2Results posted
• A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT01853228Phase 1/2Results posted
• Metformin+Cytarabine for the Treatment of Relapsed/Refractory AMLTerminatedNCT01849276Phase 1Results posted
• Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid LeukemiaTerminatedNCT01846624Phase 2Results posted
• PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell TransplantCompletedNCT01841333Phase 2Results posted
• Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01839916Phase 2Results posted
• Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML PatientsCompletedNCT01838395Phase 2Results posted
• Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).CompletedNCT01835587Phase 1/2Results posted
• Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedNCT01831232Not applicableResults posted
• Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT01829503Phase 2Results posted

← Leukemia, Myeloid, Acute overview